Wolfgang Miesbach/LinkedIn
Apr 28, 2026, 05:28
Wolfgang Miesbach: How Can the Sustainable Funding of Transformative Gene Therapies Be Ensured?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Approved Gene Therapy. For Free. In 2026.
Regeneron’s Otarmeni (lunsotogene parvec‑cwha) – the first FDA‑approved gene therapy for genetic hearing loss – will be provided at no cost to clinically eligible patients in the United States.
Under a ‘Most Favored Nation’ (MFN)–style agreement with the U.S. government, linking U.S. prices to the lowest levels observed in comparable high‑income countries, Regeneron has committed to:
- Providing Otarmeni at no cost to eligible U.S. patients (with treatment logistics and administration costs covered through established payer mechanisms).
- Aligning Medicaid pricing – as well as future U.S. launch prices for selected medicines – with international benchmark levels.
- Medicaid is the U.S. public insurance program covering tens of millions of individuals, including low‑income populations, children, people with disabilities, and older adults.
- Expanding U.S.-based manufacturing and repatriating foreign revenues within an ‘America‑first’ pricing framework.
One big question remains:
How can the sustainable funding of transformative gene therapies be ensured in a manner that is equitable for both patients and healthcare systems?”
Stay updated with Hemostasis Today.
-
Sep 22, 2026, 06:01Nikola Pantic: New ASH ITP Guidelines Transform First-Line Treatment
-
Sep 22, 2026, 04:43Michael Cahillane: Highlights From BBTS2026 in Glasgow
-
Sep 22, 2026, 04:15Wolfgang Miesbach: First AAV Gene Therapy Data in Adolescents With Haemophilia B
-
Sep 22, 2026, 04:03Emmanuel J Favaloro: 100 Years of VWD – A Special Virtual Issue
-
Sep 22, 2026, 03:31Mostafa Elshazly: How Is Humidification Used During Non Invasive Ventilation?
-
Sep 22, 2026, 03:05Sumyea Kabir: Jehovah’s Witnesses Update Their Position on Blood Components
-
Sep 22, 2026, 02:33Gerardo Moscatelli: The Spike Protein Cascade – From Endothelial Binding to Vascular Collapse
-
Sep 21, 2026, 20:56George Touma: ApoB Should Be Central to All Lipid Guidlines
-
Sep 21, 2026, 20:55Christopher Robinson: Obstetric Risks Are Seen at the Extremes of Birthweight